Dr. Kreyenbuhl's primary research focus is the pharmacoepidemiology of serious mental illness, primarily schizophrenia. She was the recipient of a K01 Research Career Award from NIMH that focused on prescription decision-making and patterns of use of complex, multidrug regimens in schizophrenia. Dr. Kreyenbuhl has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She also served as a consultant to the American Psychiatric Association (APA) during their effort to update the Practice Guideline for the Treatment of Patients with Schizophrenia in 2004. In addition, Dr. Kreyenbuhl has expertise in the area of medication adherence and has received support from NARSAD to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for side effects increases rates of screening and activates patients to discuss screening with their providers. She is currently pursuing research funding on other computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 50 publications in peer-reviewed journals.